Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01628926
First received: June 24, 2012
Last updated: April 23, 2014
Last verified: April 2014
  Purpose
  • To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962.
  • To demonstrate the superiority of SPM 962 to placebo in terms of efficacy.
  • To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.

Condition Intervention Phase
Parkinson's Disease
Drug: SPM 962
Drug: Ropinirole
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score [ Time Frame: baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.

    UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.



Secondary Outcome Measures:
  • UPDRS Part 3 Sum Score [ Time Frame: baseline, 8 and 10 weeks after dosing ] [ Designated as safety issue: No ]

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing.

    UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.


  • UPDRS Part 2 Sum Score [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.

    UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.


  • Off Time [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.

  • Parkinson's Disease Sleep Scale-2 (PDSS-2) [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.

  • On Time [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

  • On Time Without Dyskinesia Disturbing Daily Activities [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]

    Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing.

    On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.


  • On Time With Dyskinesia Disturbing Daily Activities [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).

  • Effective Rate in UPDRS Part 3 Sum Score [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.

  • Effective Rate in UPDRS Part 2 Sum Score [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.

  • Effective Rate in Off Time [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing.

    On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.


  • Clinical Global Impression (CGI) [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]

    Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.

    The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.


  • Dystonia (at an Early Hour) [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).

  • Dystonia (in the Daytime) [ Time Frame: Baseline, 16 weeks after dosing ] [ Designated as safety issue: No ]
    Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).


Enrollment: 420
Study Start Date: June 2009
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SPM 962
SPM 962 transdermal patch
Drug: SPM 962
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Active Comparator: Ropinirole
Ropinirole tablet
Drug: Ropinirole
Ropinirole oral administration TID up to 15.0 mg/day
Placebo Comparator: Placebo
SPM962 placebo patch and Ropinirole placebo tab
Drug: Placebo
SPM962-placebo patch and Ropinirole-placebo tab

  Eligibility

Ages Eligible for Study:   30 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
  • Subject is 30 and more and less than 80 years of age at the time of informed consent.
  • Hoehn & Yahr stage 2-4 (on time).
  • Total UPDRS Part 3 score is over 10 at screening test (on time).
  • Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962.
  • Subject has any of the following problematic symptoms; 1) Wearing off phenomenon (including frozen gait at off time and dystonia at off time) 2) On and off phenomenon 3) Delayed-on and/or No-on phenomenon 4) Dyskinesia 5) Not well controlled with L-dopa.

Exclusion Criteria:

  • Subject who has previously participated in a clinical trial of SPM962 and taken the investigational product (IP).
  • Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test or baseline.
  • Subject whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or subject who develops orthostatic hypotension at baseline.
  • Subject has a history of epilepsy, convulsion and other.
  • Subject who has complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the NYHA classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris).
  • Subjects has QTc-interval >450 msec twice at screening. Subject has a the average QTc-interval from two ECGs >450 msec in males and >470 msec in females at baseline.
  • Subject has congenital long QT syndrome.
  • Subject whose serum potassium level is < 3.5mEq/L at the screening test.
  • Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at screening test, or suffers complications of active phase of chronic hepatitis or liver cirrhosis.
  • Subject has BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at screening test.
  • Subject has a history of allergic reaction to topical agents such as transdermal patch.
  • Subject has a history of known intolerance/hypersensitivity to ropinirole and/or adverse drug reactions that prevent subject from receiving treatment.
  • Subject is pregnant or nursing or woman who plans pregnancy during the trial.
  • Subject is receiving therapy with prohibited drug specified in the study protocol.
  • Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Subject has dementia, including DLB and PDD (MMSE score <= 24 at screening).
  • Subject who has a complication or history of malignant neoplastic disease, or received treatment for the disease within 12 months prior to the screening test.
  • Subject is unable to give consent.
  • Subject who is unable to properly record information in a diary.
  • Subject is participating in another trial of IPs or received other IPs within 12 weeks prior to commencement of study treatment.
  • Investigator judges that subject is inappropriate as a study subject with other reasons.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01628926

Locations
Japan
Chubu Region, Japan
Chugoku Region, Japan
Hokkaido Region, Japan
Kanto Region, Japan
Kinki Region, Japan
Kyushu Region, Japan
Shikoku Region, Japan
Tohoku Region, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Investigators
Study Director: Kyoji Imaoka, Mr Otsuka Pharmaceutical Co., Ltd.
  More Information

No publications provided

Responsible Party: Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01628926     History of Changes
Other Study ID Numbers: 243-08-001, JapicCTI-090888
Study First Received: June 24, 2012
Results First Received: February 3, 2014
Last Updated: April 23, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Ropinirole
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 19, 2014